Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on February 3, 2017. The report addresses material events regarding the conversion of Series A convertible preferred stock into common stock and the resulting update to the company's outstanding share count for Nasdaq Capital Market listing compliance.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Preferred Stock Conversion: Following a public offering closed on November 29, 2016, 40 shares of Series A preferred stock were converted into 2,666,680 shares of common stock by December 16, 2016.
- Final Conversion: Between December 16, 2016, and January 31, 2017, the remaining 28 shares of Series A preferred stock were converted into an additional 1,866,676 shares of common stock.
- Capital Structure Update: As of January 31, 2017, there are no longer any Series A preferred shares outstanding.
- Outstanding Shares: The total number of common stock shares outstanding as of January 31, 2017, is 11,501,664.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The report is strictly a notification of the share conversion and the subsequent filing with Nasdaq to maintain listing status.
Key Facts for Investor Verification
- Verify the total outstanding common share count of 11,501,664 as of January 31, 2017.
- Confirm that all Series A convertible preferred stock has been fully converted and is no longer outstanding.
- Review the impact of the increased share count on potential dilution for existing common shareholders.